Hostname: page-component-7dd5485656-bvgqh Total loading time: 0 Render date: 2025-10-31T12:37:58.783Z Has data issue: false hasContentIssue false
  • English
  • Français

The effect of second-generation antipsychotics on hippocampal volume in first episode of psychosis: longitudinal study

Published online by Cambridge University Press:  02 January 2018

Michael Bodnar ,
Ashok K. Malla ,
Carolina Makowski ,
M. Mallar Chakravarty ,
Ridha Joober  and
Martin Lepage
Michael Bodnar*
Affiliation:
Prevention and Early Intervention Program for Psychoses (PEPP – Montreal), Douglas Mental Health University Institute, Montreal, Canada Department of Psychology, McGill University, Montreal, Canada
Ashok K. Malla
Affiliation:
Prevention and Early Intervention Program for Psychoses (PEPP – Montreal), Douglas Mental Health University Institute, Montreal, Canada Department of Psychiatry, McGill University, Montreal, Canada
Carolina Makowski
Affiliation:
Integrated Program in Neuroscience, McGill University, Montreal, Canada
M. Mallar Chakravarty
Affiliation:
Department of Psychiatry, McGill University, Montreal, Canada Integrated Program in Neuroscience, McGill University, Montreal, Canada
Ridha Joober
Affiliation:
Prevention and Early Intervention Program for Psychoses (PEPP – Montreal), Douglas Mental Health University Institute, Montreal, Canada Department of Psychiatry, McGill University, Montreal, Canada
Martin Lepage
Affiliation:
Prevention and Early Intervention Program for Psychoses (PEPP – Montreal), Douglas Mental Health University Institute, Montreal, Canada Department of Psychology, McGill University, Montreal, Canada Integrated Program in Neuroscience, McGill University, Montreal, Canada Department of Psychiatry, McGill University, Montreal, Canada
*
Martin Lepage, PhD, Douglas Mental Health University Institute, Frank B. Common Pavilion, F1143, 6875 LaSalle Blvd., Verdun, Quebec H4H 1R3, Canada. Email: martin.lepage@mcgill.ca
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

Current neuroscience literature has related treatment with aripiprazole to improved memory performance and subcellular changes in the hippocampus.

Aims

To explore the volumetric changes in hippocampal grey matter in people with a first episode of psychosis (FEP) treated with second-generation antipsychotics.

Method

Baseline and 1-year follow-up magnetic resonance images were obtained. Hippocampal volumes were estimated by using FreeSurfer and MAGeT-Brain. Subgroups included: aripiprazole (n=13), olanzapine (n=12), risperidone/paliperidone (n=24), refused-antipsychotics (n=13) and controls (n=44).

Results

Aripiprazole subgroup displayed significant increases in bilateral hippocampal volume compared with all other subgroups (FreeSurfer: all P's<0.012; MAGeT-Brain: all P's<0.040).

Conclusions

Aripiprazole is a first-line, second-generation treatment option that may provide an added benefit of pro-hippocampal growth. The biological underpinnings of these changes should be the focus of future investigations and may be key towards achieving a better clinical outcome for more individuals.

Information

Type
Research Article
Information
BJPsych Open , Volume 2 , Issue 2 , March 2016 , pp. 139 - 146
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Copyright
Copyright © The Royal College of Psychiatrists 2016

Footnotes

Declaration of interest

M.L. received financial assistance/compensation for research and educational events from Janssen-Ortho, Eli Lilly, Roche and Otsuka/Lundbeck Alliance. A.K.M. received financial assistance/compensation for research and educational activities from Pfizer, Janssen-Ortho, AstraZeneca and Bristol-Myers Squibb. R.J. received consultancy honorariums from Pfizer and Janssen-Ortho.

References

1 Moncrieff, J, Leo, J. A systematic review of the effects of antipsychotic drugs on brain volume. Psychol Med 2010; 40: 1409–22.Google Scholar
2 Olabi, B, Ellison-Wright, I, McIntosh, AM, Wood, SJ, Bullmore, E, Lawrie, SM. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol Psychiatry 2011; 70: 88–96.Google Scholar
3 Vita, A, De Peri, L, Deste, G, Barlati, S, Sacchetti, E. The effect of antipsychotic treatment on cortical gray matter changes in schizophrenia: does the class matter? A meta-analysis and meta-regression of longitudinal magnetic resonance imaging studies. Biol Psychiatry 2015; 78: 403–12.Google Scholar
4 Bodnar, M, Malla, AK, Czechowska, Y, Benoit, A, Fathalli, F, Joober, R, et al. Neural markers of remission in first-episode schizophrenia: a volumetric neuroimaging study of the hippocampus and amygdala. Schizophr Res 2010; 122: 72–80.Google Scholar
5 Lieberman, J, Chakos, M, Wu, H, Alvir, J, Hoffman, E, Robinson, D, et al. Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry 2001; 49: 487–99.Google Scholar
6 Bervoets, C, Morrens, M, Vansteelandt, K, Kok, F, de Patoul, A, Halkin, V, et al. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients: results from the ESCAPE study. CNS Drugs 2012; 26: 975–82.Google Scholar
7 Kern, RS, Green, MF, Cornblatt, BA, Owen, JR, McQuade, RD, Carson, WH, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology 2006; 187: 312–20.Google Scholar
8 Riedel, M, Spellmann, I, Schennach-Wolff, R, Musil, R, Dehning, S, Cerovecki, A, et al. Effect of aripiprazole on cognition in the treatment of patients with schizophrenia. Pharmacopsychiatry 2010; 43: 50–7.Google Scholar
9 First, MB, Gibbon, M, Spitzer, RL, Williams, JBW, Benjamin, LS. Structured Clinical Interview for DSM-IV Axis I Disorders, Research DVersion, Patient VEdition. American Psychiatric Press, 1997.Google Scholar
10 Iyer, S, Jordan, G, MacDonald, K, Joober, R, Malla, A. Early intervention for psychosis: a Canadian perspective. J Nerv Ment Dis. 2015; 203: 356–64.Google Scholar
11 Woods, SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64: 663–7.Google Scholar
12 Woods, SW. C hlorpromazine Equivalent Doses for Atypical Antipsychotics: An Update 2003–2010. Available at: http://www.scottwilliamwoods.com/files/WoodsEquivUpdate.doc (accessed 29 Feb 2016).Google Scholar
13 Hollingshead, A. Two-Factor Index of Social Position. Yale University Press, 1965.Google Scholar
14 Oldfield, RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychology 1971; 9: 97–113.Google Scholar
15 Wechsler, D. Wecshler Adult Intelligence Scale (3rd edn). The Psychological Corporation, 1997.Google Scholar
16 Wechsler, D. Wechsler Abbreviated Scale of Intelligence. The Psychological Corporation, 1999.Google Scholar
17 Malla, AK, Norman, RM, Manchanda, R, Townsend, L. Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis. Psychol Med 2002; 32: 1109–19.Google Scholar
18 Malla, A, Norman, R, Schmitz, N, Manchanda, R, Bechard-Evans, L, Takhar, J, et al. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychol Med 2006; 36: 649–58.Google Scholar
19 Andreasen, NC. Scale for the Assessment of Positive Symptoms (SAPS). University of Iowa, 1984.Google Scholar
20 Andreasen, NC. Modified Scale for the Assessment of Negative Symptoms (SANS). University of Iowa, 1984.Google Scholar
21 Andreasen, NC, Carpenter, WT Jr, Kane, JM, Lasser, RA, Marder, SR, Weinberger, DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441–9.Google Scholar
22 Van Leemput, K, Bakkour, A, Benner, T, Wiggins, G, Wald, LL, Augustinack, J, et al. Automated segmentation of hippocampal subfields from ultra-high resolution in vivo MRI. Hippocampus 2009; 19: 549–57.Google Scholar
23 Reuter, M, Fischl, B. Avoiding asymmetry-induced bias in longitudinal image processing. NeuroImage 2011; 57: 19–21.Google Scholar
24 Reuter, M, Schmansky, NJ, Rosas, HD, Fischl, B. Within-subject template estimation for unbiased longitudinal image analysis. NeuroImage 2012; 61: 1402–18.Google Scholar
25 Chakravarty, MM, Steadman, P, van Eede, MC, Calcott, RD, Gu, V, Shaw, P, et al. Performing label-fusion-based segmentation using multiple automatically generated templates. Hum Brain Mapp 2013; 34: 2635–54.Google Scholar
26 Winterburn, JL, Pruessner, JC, Chavez, S, Schira, MM, Lobaugh, NJ, Voineskos, AN, et al. A novel in vivo atlas of human hippocampal subfields using high-resolution 3 T magnetic resonance imaging. NeuroImage 2013; 74: 254–65.Google Scholar
27 Pipitone, J, Park, MT, Winterburn, J, Lett, TA, Lerch, JP, Pruessner, JC, et al. Multi-atlas segmentation of the whole hippocampus and subfields using multiple automatically generated templates. NeuroImage 2014; 101: 494–512.Google Scholar
28 Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23.Google Scholar
29 Stip, E, Anselmo, K. Effectiveness of antipsychotics: is the CATIE trial a tsunami? Can Fam Physician 2007; 53: 97–8.Google Scholar
30 Cassidy, CM, Rabinovitch, M, Schmitz, N, Joober, R, Malla, A. A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis. J Clin Psychopharmacol 2010; 30: 64–7.Google Scholar
31 Fu, DJ, Bossie, CA, Sliwa, JK, Ma, YW, Alphs, L. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. Int Clin Psychopharmacol 2014; 29: 45–55.Google Scholar
32 Spalding, KL, Bergmann, O, Alkass, K, Bernard, S, Salehpour, M, Huttner, HB, et al. Dynamics of hippocampal neurogenesis in adult humans. Cell 2013; 153: 1219–27.Google Scholar
33 Deng, W, Aimone, JB, Gage, FH. New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? Nat Rev Neurosci 2010; 11: 339–50.Google Scholar
34 Russo, E, Citraro, R, Davoli, A, Gallelli, L, Di Paola, ED, De Sarro, G. Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology 2013; 64: 371–9.Google Scholar
35 Nagai, T, Murai, R, Matsui, K, Kamei, H, Noda, Y, Furukawa, H, et al. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology 2009; 202: 315–28.Google Scholar
36 Nowakowska, E, Kus, K, Ratajczak, P, Cichocki, M, Wozniak, A. The influence of aripiprazole, olanzapine and enriched environment on depressant-like behavior, spatial memory dysfunction and hippocampal level of BDNF in prenatally stressed rats. Pharmacol Rep 2014; 66: 404–11.Google Scholar
37 Li, Z, Ichikawa, J, Dai, J, Meltzer, HY. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 2004; 493: 75–83.Google Scholar
38 Yoneyama, M, Hasebe, S, Kawamoto, N, Shiba, T, Yamaguchi, T, Kikuta, M, et al. Beneficial in vivo effect of aripiprazole on neuronal regeneration following neuronal loss in the dentate gyrus: evaluation using a mouse model of trimethyltin-induced neuronal loss/self-repair in the dentate gyrus. J Pharmacol Sci 2014; 124: 99–111.Google Scholar
39 Schlagenhauf, F, Dinges, M, Beck, A, Wustenberg, T, Friedel, E, Dembler, T, et al. Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation. Schizophr Res 2010; 118: 189–200.Google Scholar
40 Schreiber, R, Newman-Tancredi, A. Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation. Neurobiol Learn Memory 2014; 110: 72–80.Google Scholar
41 Halim, ND, Weickert, CS, McClintock, BW, Weinberger, DR, Lipska, BK. Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 2004; 29: 1063–9.Google Scholar
42 Chen, BH, Yan, BC, Park, JH, Ahn, JH, Lee, DH, Kim, IH, et al. Aripiprazole, an atypical antipsychotic drug, improves maturation and complexity of neuroblast dendrites in the mouse dentate gyrus via increasing superoxide dismutases. Neurochem Res 2013; 38: 1980–8.Google Scholar
43 Maeda, K, Sugino, H, Hirose, T, Kitagawa, H, Nagai, T, Mizoguchi, H, et al. Clozapine prevents a decrease in neurogenesis in mice repeatedly treated with phencyclidine. J Pharmacol Sci 2007; 103: 299–308.Google Scholar
44 Gao, J, Qin, R, Li, M. Repeated administration of aripiprazole produces a sensitization effect in the suppression of avoidance responding and phencyclidine-induced hyperlocomotion and increases D2 receptor-mediated behavioral function. J Psychopharmacol 2015; 29: 390–400.Google Scholar
45 Egan, MF, Kojima, M, Callicott, JH, Goldberg, TE, Kolachana, BS, Bertolino, A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257–69.Google Scholar
46 Park, SW, Lee, JG, Ha, EK, Choi, SM, Cho, HY, Seo, MK, et al. Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells. Eur Neuropsychopharmacol 2009; 19: 356–62.Google Scholar
47 Binder, DK, Scharfman, HE. Brain-derived neurotrophic factor. Growth Factors 2004; 22: 123–31.Google Scholar
48 Kuhn, S, Musso, F, Mobascher, A, Warbrick, T, Winterer, G, Gallinat, J. Hippocampal subfields predict positive symptoms in schizophrenia: first evidence from brain morphometry. Transl Psychiatry 2012; 2: e127.Google Scholar
49 Mathew, I, Gardin, TM, Tandon, N, Eack, S, Francis, AN, Seidman, LJ, et al. Medial temporal lobe structures and hippocampal subfields in psychotic disorders: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. JAMA Psychiatry 2014; 71: 769–77.Google Scholar
50 Kawano, M, Sawada, K, Shimodera, S, Ogawa, Y, Kariya, S, Lang, DJ, et al. Hippocampal subfield volumes in first episode and chronic schizophrenia. PLoS One 2015; 10: e0117785.Google Scholar
51 Wisse, LE, Biessels, GJ, Geerlings, MI. A critical appraisal of the hippocampal subfield segmentation package in freeSurfer. Front Aging Neurosci 2014; 6: 261.Google Scholar
Supplementary material: PDF

Bodnar et al. supplementary material

Supplementary Material

Download Bodnar et al. supplementary material(PDF)
PDF 210.4 KB
Submit a response

eLetters

No eLetters have been published for this article.